Sales of Hypertrophic Cardiomyopathy (HCM) Therapeutics to Reach US $1.3 Bn by the End of 2023, Reports TMR
The global hypertrophic cardiomyopathy (HCM) therapeutics market is dominated by companies exhibiting high sales. However, generic manufacturers are making their presence felt in the market gradually. As per Transparency Market Research (TMR), the top three companies in the market, Sanofi S.A., Pfizer, Inc., and Merck & Co., accounted for a share of over 64.5%, which points toward a highly consolidated vendor landscape.
View full press release